Abstract
Objectives To examine trends in long-term (>6 months) vaping among adults in England.
Design Nationally-representative monthly cross-sectional survey.
Setting England.
Participants 179,725 adults (≥18y) surveyed between October 2013 and October 2023.
Main outcome measures We used logistic regression to estimate time trends in the prevalence of long-term vaping, overall and by vaping frequency (daily/non-daily) and the main device type used (disposable/refillable/pod).
Results The proportion of adults reporting long-term vaping increased non-linearly from 1.3% [95%CI 1.1-1.5%] in October 2013 to 10.0% [9.2-10.9%] in October 2023, with a particularly pronounced rise since 2021. This included an increase in long-term daily vaping, which rose from 0.6% [0.5-0.8%] to 6.7% [6.0-7.4%], respectively. The absolute increases in long-term vaping were most pronounced among ever smokers (current smokers: 4.8% [4.0-5.8%] to 23.1% [20.4-25.9%]; recent ex-smokers: 5.7% [3.4-9.2%] to 36.1% [27.6-45.4%]; long-term ex-smokers: 1.4% [1.0-1.9%] to 16.2% [14.2-18.4%]), but there was also an increase among never smokers (0.1% [0.0-0.2%] to 3.0% [2.3-3.8%]). Growth was also most pronounced in younger adults (e.g., reaching 22.7% [19.2-26.5%] of 18-year-olds vs. 4.3% [3.6-5.2%] of 65-year-olds), including among never smokers (reaching 16.1% [11.1-22.7%] among 18-year-olds vs. 0.3% [0.1-0.6%] of 65-year-olds). Up to March 2021, most long-term vapers mainly/exclusively used refillable e-cigarettes (2.5-3.3% of adults) and very few (0.1% of adults) used disposables. However, prevalence of long-term disposable vaping subsequently rose rapidly and by October 2023, similar proportions mainly/exclusively used refillable and disposable devices (4.6% [4.0-5.3%] and 4.9% [4.2-5.7%] of adults, respectively).
Conclusions The prevalence of long-term (>6 months) vaping has increased substantially among adults in England over the past decade. Much of this increase in prevalence has occurred since 2021, coinciding with the rapid rise in popularity of disposable e-cigarettes. Half of long-term vapers now mainly or exclusively use disposable devices. The growth has been concentrated among ever smokers but there has also been an increase among never smokers, especially younger adults.
What is already known on this topic
Vaping prevalence has increased substantially in England since new disposable e-cigarettes became popular in mid-2021, particularly among young people.
It is not clear how far this reflects an increase in experimental use versus long-term, regular use.
In addition, little is known about how the types of products used by long-term vapers is changing over time.
What this study adds
There has been an exceptionally steep rise in long-term vaping among young adults since 2021, including among never smoking youth, and it does not yet show signs of stopping.
Half of long-term vapers now mainly or exclusively use disposables, and most are using them every day.
Therefore, urgent action is needed to curb the rise in vaping among young people and encourage long-term vapers to transition to less environmentally damaging products.
Competing Interest Statement
JB has received unrestricted research funding from Pfizer and J&J, who manufacture smoking cessation medications. LS has received honoraria for talks, unrestricted research grants and travel expenses to attend meetings and workshops from manufactures of smoking cessation medications (Pfizer; J&J), and has acted as paid reviewer for grant awarding bodies and as a paid consultant for health care companies. All authors declare no financial links with tobacco companies, e-cigarette manufacturers, or their representatives.
Clinical Protocols
Funding Statement
This study was funded by Cancer Research UK (PRCRPG-Nov21\100002).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethical approval for the STS was granted originally by the UCL Ethics Committee (ID 0498/001). The data are not collected by UCL and are anonymized when received by UCL.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
The data used for these analyses are available on Open Science Framework (https://osf.io/n2785/), with age provided in bands to preserve participant anonymity.
